The US has imposed a 100% tariff on branded and patented pharmaceuticals, targeting imports from India’s $10 billion export industry. While generics remain unaffected for now, uncertainty persists around complex drugs. Sun Pharma, Dr. Reddy’s, Cipla, and Zydus face the highest risks due to significant US revenue exposure.